Curbing gastrointestinal infections by defensin fragment modifications without harming commensal microbiota.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Marina C Pils, Marina C.
Nisar P Malek, Nisar P.
Heike Brötz-Oesterhelt, Heike
MetadataShow full item record
AbstractThe occurrence and spread of multidrug-resistant pathogens, especially bacteria from the ESKAPE panel, increases the risk to succumb to untreatable infections. We developed a novel antimicrobial peptide, Pam-3, with antibacterial and antibiofilm properties to counter this threat. The peptide is based on an eight-amino acid carboxyl-terminal fragment of human β-defensin 1. Pam-3 exhibited prominent antimicrobial activity against multidrug-resistant ESKAPE pathogens and additionally eradicated already established biofilms in vitro, primarily by disrupting membrane integrity of its target cell. Importantly, prolonged exposure did not result in drug-resistance to Pam-3. In mouse models, Pam-3 selectively reduced acute intestinal Salmonella and established Citrobacter infections, without compromising the core microbiota, hence displaying an added benefit to traditional broad-spectrum antibiotics. In conclusion, our data support the development of defensin-derived antimicrobial agents as a novel approach to fight multidrug-resistant bacteria, where Pam-3 appears as a particularly promising microbiota-preserving candidate.
CitationCommun Biol. 2021 Jan 8;4(1):47. doi: 10.1038/s42003-020-01582-0.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
- Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin peptide conjugate.
- Authors: Mohamed MF, Brezden A, Mohammad H, Chmielewski J, Seleem MN
- Issue date: 2017 Apr
- The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms.
- Authors: de Breij A, Riool M, Cordfunke RA, Malanovic N, de Boer L, Koning RI, Ravensbergen E, Franken M, van der Heijde T, Boekema BK, Kwakman PHS, Kamp N, El Ghalbzouri A, Lohner K, Zaat SAJ, Drijfhout JW, Nibbering PH
- Issue date: 2018 Jan 10
- Antimicrobial polymers as therapeutics for treatment of multidrug-resistant Klebsiella pneumoniae lung infection.
- Authors: Lou W, Venkataraman S, Zhong G, Ding B, Tan JPK, Xu L, Fan W, Yang YY
- Issue date: 2018 Sep 15
- An <i>In Vitro</i> Chicken Gut Model Demonstrates Transfer of a Multidrug Resistance Plasmid from <i>Salmonella</i> to Commensal <i>Escherichia coli</i>.
- Authors: Card RM, Cawthraw SA, Nunez-Garcia J, Ellis RJ, Kay G, Pallen MJ, Woodward MJ, Anjum MF
- Issue date: 2017 Jul 18
- Fragmentation of Human Neutrophil α-Defensin 4 to Combat Multidrug Resistant Bacteria.
- Authors: Ehmann D, Koeninger L, Wendler J, Malek NP, Stange EF, Wehkamp J, Jensen BAH
- Issue date: 2020